<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536093</url>
  </required_header>
  <id_info>
    <org_study_id>OAC-01-ELGAN</org_study_id>
    <nct_id>NCT01536093</nct_id>
  </id_info>
  <brief_title>Oropharyngeal Administration of Colostrum to Extremely Low Gestational Age Newborns</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colostrum is rich in cytokines and other immune agents that may provide immunomodulatory
      protection against nosocomial infection in extremely premature infants. However, most of them
      could not proceed enteral feedings due to clinical instability in the first few days. Recent
      studies supports oropharyngeal administration as a potentially safe and effective delivery
      method for immunologic benefits and only small amount of colostrum could be administrated for
      immune therapy for extremely premature babies. The purpose of this study is to determine the
      beneficial effects of oropharyngeal administration of colostrum for immunologic aspects in
      extremely low gestational age infants and evaluated the safety of this method to extremely
      premature infants in the first few days of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Secretary IgA Concentration at 2 Weeks of Age</measure>
    <time_frame>2 weeks of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Secretary IgA Concentration at 1 Week of Age</measure>
    <time_frame>1 week of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary TGF-beta 1 Concentration at 2 Week of Age</measure>
    <time_frame>2 week of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary IL-8 Concentration at 2 Weeks of Age</measure>
    <time_frame>2 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Urinary Lactoferrin</measure>
    <time_frame>1 week of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Urinary IL-1 Beta</measure>
    <time_frame>2 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Salivary Lactoferrin, Lysozyme, Alpha-lactalbumin and Cytokines</measure>
    <time_frame>1 week of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Salivary Lactoferrin, Lysozyme, Alpha-lactalbumin and Cytokines</measure>
    <time_frame>2 weeks of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Full Feeding</measure>
    <time_frame>up to 2 months of age</time_frame>
    <description>day of life when the baby reaches full enteral feeding, defined as a volume above 120~130mL/kg/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Hospital Admission Duration</measure>
    <time_frame>up to 4 months of age</time_frame>
    <description>days from admission to discharge from NICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Culture Positive Sepsis</measure>
    <time_frame>from date of randomization up to 4 months of age</time_frame>
    <description>numbers of documented sepsis events defined as isolation of the microorganism from ≥ 1 blood culture + ≥ 1 clinical symptoms or sign (fever, hypothermia, apnea, bradycardia, hypo-/hyperglycemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Necrotizing Enterocolitis ≥ Bell's Stage 2</measure>
    <time_frame>from date of randomization up to 4 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of Pneumonia</measure>
    <time_frame>from date of randomization up to 4 months of age</time_frame>
    <description>numbers of documented pneumonia events those accompanied with increased tracheal secretion, increased ventilatory setting and treated with antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Bronchopulmonary Dysplasia ≥ Moderate</measure>
    <time_frame>up to 4 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Intraventricular Hemorrhage ≥ Grade 3</measure>
    <time_frame>up to 4 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Death</measure>
    <time_frame>up to 4 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Adverse Effects</measure>
    <time_frame>from the start date of oropharyngeal administration of colostrum or sterile water to 1 week of age</time_frame>
    <description>category of adverse effects
general - fever or hypothermia, rash
respiratory &amp; cardiovascular - apnea, tachypnea, desaturation, hypotension, bradycardia, tachycardia
gastrointestinal - abdominal distension, bilious gastric remain, vomiting, bloody stool, necrotizing enterocolitis
renal - oliguria (urine output &lt; 1.0cc/kg/day)
laboratory - hypo-/hyper-natremia, acidosis, hypercarbia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Extremely Low Gestational Age Newborn</condition>
  <condition>Premature Infant</condition>
  <arm_group>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oropharyngeal administration of own mother's colostrum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oropharyngeal administration of sterile water</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oropharyngeal administration of own mother's colostrum</intervention_name>
    <description>application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
    <arm_group_label>Colostrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oropharyngeal administration of sterile water</intervention_name>
    <description>application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature infant with a gestational age less than 28 weeks born at Seoul National
             University Hospital and admit to the Seoul National University Children's Hospital
             NICU immediately after birth

          -  parents of the infant signed to the informed consent form with voluntary agreement

        Exclusion Criteria:

          -  infants with major congenital anomalies or chromosomal syndromes

          -  infants of mothers not willing to provide colostrum in the first week of life

          -  infants of mothers with known infectious diseases that may be transmitted through the
             breast milk such as HIV, hepatitis C or active TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>96 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <results_first_submitted>July 17, 2014</results_first_submitted>
  <results_first_submitted_qc>July 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2014</results_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Han-Suk Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colostrum</title>
          <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>absence of maternal colostrum</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colostrum</title>
          <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Gestational Age</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="1.4"/>
                    <measurement group_id="B2" value="26.0" spread="1.4"/>
                    <measurement group_id="B3" value="26.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight</title>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="862.2" spread="234.8"/>
                    <measurement group_id="B2" value="842.4" spread="250.4"/>
                    <measurement group_id="B3" value="849.3" spread="239.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Secretary IgA Concentration at 2 Weeks of Age</title>
        <time_frame>2 weeks of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Secretary IgA Concentration at 2 Weeks of Age</title>
          <units>ng per g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.8" spread="37.4"/>
                    <measurement group_id="O2" value="48.3" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Secretary IgA Concentration at 1 Week of Age</title>
        <time_frame>1 week of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Secretary IgA Concentration at 1 Week of Age</title>
          <units>ng per g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="33.1"/>
                    <measurement group_id="O2" value="26.5" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Salivary TGF-beta 1 Concentration at 2 Week of Age</title>
        <time_frame>2 week of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary TGF-beta 1 Concentration at 2 Week of Age</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="6.3"/>
                    <measurement group_id="O2" value="69.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Salivary IL-8 Concentration at 2 Weeks of Age</title>
        <time_frame>2 weeks of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Salivary IL-8 Concentration at 2 Weeks of Age</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="1.01"/>
                    <measurement group_id="O2" value="4.90" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Urinary Lactoferrin</title>
        <time_frame>1 week of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Urinary Lactoferrin</title>
          <units>ug per g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.32"/>
                    <measurement group_id="O2" value="0.98" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Urinary IL-1 Beta</title>
        <time_frame>2 weeks of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colostrum</title>
            <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Urinary IL-1 Beta</title>
          <units>ug per g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.25" spread="7.12"/>
                    <measurement group_id="O2" value="91.80" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Salivary Lactoferrin, Lysozyme, Alpha-lactalbumin and Cytokines</title>
        <time_frame>1 week of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Salivary Lactoferrin, Lysozyme, Alpha-lactalbumin and Cytokines</title>
        <time_frame>2 weeks of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Full Feeding</title>
        <description>day of life when the baby reaches full enteral feeding, defined as a volume above 120~130mL/kg/day</description>
        <time_frame>up to 2 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hospital Admission Duration</title>
        <description>days from admission to discharge from NICU</description>
        <time_frame>up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Culture Positive Sepsis</title>
        <description>numbers of documented sepsis events defined as isolation of the microorganism from ≥ 1 blood culture + ≥ 1 clinical symptoms or sign (fever, hypothermia, apnea, bradycardia, hypo-/hyperglycemia)</description>
        <time_frame>from date of randomization up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Necrotizing Enterocolitis ≥ Bell's Stage 2</title>
        <time_frame>from date of randomization up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episodes of Pneumonia</title>
        <description>numbers of documented pneumonia events those accompanied with increased tracheal secretion, increased ventilatory setting and treated with antibiotics</description>
        <time_frame>from date of randomization up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Bronchopulmonary Dysplasia ≥ Moderate</title>
        <time_frame>up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Intraventricular Hemorrhage ≥ Grade 3</title>
        <time_frame>up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Death</title>
        <time_frame>up to 4 months of age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Adverse Effects</title>
        <description>category of adverse effects
general - fever or hypothermia, rash
respiratory &amp; cardiovascular - apnea, tachypnea, desaturation, hypotension, bradycardia, tachycardia
gastrointestinal - abdominal distension, bilious gastric remain, vomiting, bloody stool, necrotizing enterocolitis
renal - oliguria (urine output &lt; 1.0cc/kg/day)
laboratory - hypo-/hyper-natremia, acidosis, hypercarbia</description>
        <time_frame>from the start date of oropharyngeal administration of colostrum or sterile water to 1 week of age</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Colostrum</title>
          <description>oropharyngeal administration of own mother's colostrum
oropharyngeal administration of own mother's colostrum: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>oropharyngeal administration of sterile water
oropharyngeal administration of sterile water: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juyoung Lee</name_or_title>
      <organization>Seoul National University College of Medicine</organization>
      <phone>82-31-787-7301</phone>
      <email>lamb4122@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

